Associations of sNfL with clinico-radiological measures in a large MS population.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
03
11
2022
received:
19
09
2022
accepted:
08
11
2022
pubmed:
26
11
2022
medline:
24
1
2023
entrez:
25
11
2022
Statut:
ppublish
Résumé
Evaluation of serum neurofilament light chain (sNfL), measured using high-throughput assays on widely accessible platforms in large, real-world MS populations, is a critical step for sNfL to be utilized in clinical practice. Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) is a network of healthcare institutions in the United States and Europe collecting standardized clinical/imaging data and biospecimens during routine clinic visits. sNfL was measured in 6974 MS and 201 healthy control (HC) participants, using a high-throughput, scalable immunoassay. Elevated sNfL levels for age (sNfL-E) were found in 1238 MS participants (17.8%). Factors associated with sNfL-E included male sex, younger age, progressive disease subtype, diabetes mellitus, impaired renal function, and active smoking. Higher body mass index (BMI) was associated with lower odds of elevated sNfL. Active treatment with disease-modifying therapy was associated with lower odds of sNfL-E. MS participants with sNfL-E exhibited worse neurological function (patient-reported disability, walking speed, manual dexterity, and cognitive processing speed), lower brain parenchymal fraction, and higher T2 lesion volume. Longitudinal analyses revealed accelerated short-term rates of whole brain atrophy in sNfL-E participants and higher odds of new T2 lesion development, although both MS participants with or without sNfL-E exhibited faster rates of whole brain atrophy compared to HC. Findings were consistent in analyses examining age-normative sNfL Z-scores as a continuous variable. Elevated sNfL is associated with clinical disability, inflammatory disease activity, and whole brain atrophy in MS, but interpretation needs to account for comorbidities including impaired renal function, diabetes, and smoking.
Identifiants
pubmed: 36427295
doi: 10.1002/acn3.51704
pmc: PMC9852396
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
84-97Subventions
Organisme : NINDS NIH HHS
ID : K23 NS117883
Pays : United States
Organisme : NIH HHS
ID : K23NS117883
Pays : United States
Organisme : NIH HHS
ID : U01NS111678
Pays : United States
Organisme : NIH HHS
ID : K01MH121582
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Bone Marrow Transplant. 2020 Apr;55(4):675-680
pubmed: 31576022
Front Neurosci. 2018 Dec 11;12:930
pubmed: 30618559
Sci Rep. 2020 Nov 23;10(1):20350
pubmed: 33230211
N Engl J Med. 2021 Nov 4;385(19):1737-1749
pubmed: 34554658
Mult Scler. 2017 Dec;23(14):1929-1937
pubmed: 28080262
Adv Ther. 2019 Jul;36(7):1741-1755
pubmed: 31054035
JAMA Neurol. 2019 Nov 01;76(11):1359-1366
pubmed: 31403661
JAMA Neurol. 2019 Sep 01;76(9):1035-1048
pubmed: 31206160
Curr Neurol Neurosci Rep. 2020 May 26;20(7):24
pubmed: 32458308
Mult Scler Relat Disord. 2022 Mar;59:103676
pubmed: 35158190
Eur J Neurol. 2020 May;27(5):878-886
pubmed: 32009276
Ann Neurol. 2022 Oct;92(4):688-698
pubmed: 35730070
J Lab Autom. 2016 Aug;21(4):533-47
pubmed: 26077162
J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):126-9
pubmed: 25716934
Nat Rev Neurol. 2009 Oct;5(10):542-51
pubmed: 19724248
Aging (Albany NY). 2021 Dec 18;13(24):25729-25738
pubmed: 34923481
Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491
pubmed: 30564615
Lancet Neurol. 2022 Mar;21(3):246-257
pubmed: 35182510
Neuroimage Clin. 2019;23:101938
pubmed: 31491829
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Neurology. 2002 Dec 10;59(11):1799-801
pubmed: 12473777
JAMA Neurol. 2020 Feb 1;77(2):245-253
pubmed: 31841592
Am J Clin Pathol. 2010 Feb;133(2):180-6
pubmed: 20093226
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
Mult Scler. 2020 Mar;26(3):312-321
pubmed: 30741108
Front Neurol. 2022 Jul 25;13:935382
pubmed: 35959400
J Neurol Sci. 2005 Jun 15;233(1-2):183-98
pubmed: 15896809
N Engl J Med. 2018 Jan 11;378(2):169-180
pubmed: 29320652
Brain. 2021 Nov 29;144(10):2954-2963
pubmed: 34180982
Sci Rep. 2020 Nov 17;10(1):19982
pubmed: 33203974
J Clin Epidemiol. 1996 Jan;49(1):79-83
pubmed: 8598515
Front Neurol. 2020 Aug 07;11:632
pubmed: 32849170
BMC Neurol. 2013 Apr 25;13:37
pubmed: 23617555
Sci Rep. 2021 May 26;11(1):11034
pubmed: 34040118
Ann Clin Transl Neurol. 2020 Jan;7(1):139-143
pubmed: 31893563